Blair Leavitt Publications

  • Gregory, S, Long, JD, Klöppel, S, Razi, A, Scheller, E, Minkova, L et al.. Operationalizing compensation over time in neurodegenerative disease. Brain. 2017; :. doi: 10.1093/brain/awx022. PubMed PMID:28334888 .
  • McColgan, P, Razi, A, Gregory, S, Seunarine, KK, Durr, A, A C Roos, R et al.. Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. Hum Brain Mapp. 2017; :. doi: 10.1002/hbm.23527. PubMed PMID:28294457 .
  • McColgan, P, Gregory, S, Razi, A, Seunarine, KK, Gargouri, F, Durr, A et al.. White matter predicts functional connectivity in premanifest Huntington's disease. Ann Clin Transl Neurol. 2017;4 (2):106-118. doi: 10.1002/acn3.384. PubMed PMID:28168210 PubMed Central PMC5288460.
  • Disatnik, MH, Joshi, AU, Saw, NL, Shamloo, M, Leavitt, BR, Qi, X et al.. Potential biomarkers to follow the progression and treatment response of Huntington's disease. J. Exp. Med. 2016;213 (12):2655-2669. doi: 10.1084/jem.20160776. PubMed PMID:27821553 PubMed Central PMC5110026.
  • Orth, M, Gregory, S, Scahill, RI, Mayer, IS, Minkova, L, Klöppel, S et al.. Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. Hum Brain Mapp. 2016;37 (12):4615-4628. doi: 10.1002/hbm.23332. PubMed PMID:27477323 .
  • Rodrigues, FB, Byrne, L, McColgan, P, Robertson, N, Tabrizi, SJ, Leavitt, BR et al.. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. J. Neurochem. 2016;139 (1):22-5. doi: 10.1111/jnc.13719. PubMed PMID:27344050 PubMed Central PMC5053298.
  • Labuschagne, I, Cassidy, AM, Scahill, RI, Johnson, EB, Rees, E, O'Regan, A et al.. Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. J Int Neuropsychol Soc. 2016;22 (6):595-608. doi: 10.1017/S1355617716000321. PubMed PMID:27211109 .
  • Connolly, C, Magnusson-Lind, A, Lu, G, Wagner, PK, Southwell, AL, Hayden, MR et al.. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience. 2016;325 :74-88. doi: 10.1016/j.neuroscience.2016.03.031. PubMed PMID:27033979 .
  • De Souza, RA, Islam, SA, McEwen, LM, Mathelier, A, Hill, A, Mah, SM et al.. DNA methylation profiling in human Huntington's disease brain. Hum. Mol. Genet. 2016;25 (10):2013-2030. doi: 10.1093/hmg/ddw076. PubMed PMID:26953320 .
  • Petkau, TL, Hill, A, Leavitt, BR. Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. Neuroscience. 2016;315 :175-95. doi: 10.1016/j.neuroscience.2015.12.006. PubMed PMID:26701296 .
  • Minkova, L, Scheller, E, Peter, J, Abdulkadir, A, Kaller, CP, Roos, RA et al.. Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. Front Hum Neurosci. 2015;9 :634. doi: 10.3389/fnhum.2015.00634. PubMed PMID:26635585 PubMed Central PMC4658414.
  • Klöppel, S, Gregory, S, Scheller, E, Minkova, L, Razi, A, Durr, A et al.. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine. 2015;2 (10):1420-9. doi: 10.1016/j.ebiom.2015.08.002. PubMed PMID:26629536 PubMed Central PMC4634199.
  • Johnson, EB, Rees, EM, Labuschagne, I, Durr, A, Leavitt, BR, Roos, RA et al.. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia. 2015;79 (Pt A):138-46. doi: 10.1016/j.neuropsychologia.2015.10.033. PubMed PMID:26519555 .
  • Minkova, L, Eickhoff, SB, Abdulkadir, A, Kaller, CP, Peter, J, Scheller, E et al.. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. Hum Brain Mapp. 2016;37 (1):67-80. doi: 10.1002/hbm.23014. PubMed PMID:26453902 .
  • Wagner, L, Wolf, R, Zeitschel, U, Rossner, S, Petersén, Å, Leavitt, BR et al.. Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery. J. Neurochem. 2015;135 (5):1019-37. doi: 10.1111/jnc.13378. PubMed PMID:26442809 .
  • Mazarei, G, Leavitt, BR. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease. J Huntingtons Dis. 2015;4 (2):109-18. doi: 10.3233/JHD-159003. PubMed PMID:26397892 PubMed Central PMC4923717.
  • Howard, AK, Krishnamoorthy, A, Leavitt, BR, Raymond, LA, Weissman, CR. Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole. J Neuropsychiatry Clin Neurosci. 2015;27 (3):e211-2. doi: 10.1176/appi.neuropsych.14090232. PubMed PMID:26222972 .
  • Southwell, AL, Smith, SE, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y et al.. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5 :12166. doi: 10.1038/srep12166. PubMed PMID:26174131 PubMed Central PMC4502413.
  • Jan, A, Karasinska, JM, Kang, MH, de Haan, W, Ruddle, P, Kaur, A et al.. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected]. Neurosci. Lett. 2015;598 :66-72. doi: 10.1016/j.neulet.2015.05.007. PubMed PMID:25957561 .
  • Bečanović, K, Nørremølle, A, Neal, SJ, Kay, C, Collins, JA, Arenillas, D et al.. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 2015;18 (6):807-16. doi: 10.1038/nn.4014. PubMed PMID:25938884 .
  • Wild, EJ, Boggio, R, Langbehn, D, Robertson, N, Haider, S, Miller, JR et al.. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J. Clin. Invest. 2015;125 (5):1979-86. doi: 10.1172/JCI80743. PubMed PMID:25844897 PubMed Central PMC4463213.
  • Callaghan, J, Stopford, C, Arran, N, Boisse, MF, Coleman, A, Santos, RD et al.. Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci. 2015;27 (1):59-64. doi: 10.1176/appi.neuropsych.13070169. PubMed PMID:25716488 .
  • Sturrock, A, Laule, C, Wyper, K, Milner, RA, Decolongon, J, Dar Santos, R et al.. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov. Disord. 2015;30 (3):393-401. doi: 10.1002/mds.26118. PubMed PMID:25690257 .
  • Bates, GP, Dorsey, R, Gusella, JF, Hayden, MR, Kay, C, Leavitt, BR et al.. Huntington disease. Nat Rev Dis Primers. 2015;1 :15005. doi: 10.1038/nrdp.2015.5. PubMed PMID:27188817 .
  • Träger, U, Andre, R, Magnusson-Lind, A, Miller, JR, Connolly, C, Weiss, A et al.. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol. Dis. 2015;73 :388-98. doi: 10.1016/j.nbd.2014.10.012. PubMed PMID:25447230 PubMed Central PMC4262574.
  • De Souza, RA, Leavitt, BR. Neurobiology of Huntington's Disease. Curr Top Behav Neurosci. 2015;22 :81-100. doi: 10.1007/7854_2014_353. PubMed PMID:25205327 .
  • Reilmann, R, Leavitt, BR, Ross, CA. Huntington's disease: a field on the move. Introduction. Mov. Disord. 2014;29 (11):1333-4. doi: 10.1002/mds.26017. PubMed PMID:25164859 .
  • Reilmann, R, Leavitt, BR, Ross, CA. Diagnostic criteria for Huntington's disease based on natural history. Mov. Disord. 2014;29 (11):1335-41. doi: 10.1002/mds.26011. PubMed PMID:25164527 .
  • Jones, R, Stout, JC, Labuschagne, I, Say, M, Justo, D, Coleman, A et al.. The potential of composite cognitive scores for tracking progression in Huntington's disease. J Huntingtons Dis. 2014;3 (2):197-207. doi: 10.3233/JHD-140101. PubMed PMID:25062862 .
  • Plecash, AR, Leavitt, BR. Aquatherapy for neurodegenerative disorders. J Huntingtons Dis. 2014;3 (1):5-11. doi: 10.3233/JHD-140010. PubMed PMID:25062761 .
  • Petkau, TL, Leavitt, BR. Progranulin in neurodegenerative disease. Trends Neurosci. 2014;37 (7):388-98. doi: 10.1016/j.tins.2014.04.003. PubMed PMID:24800652 .
  • Wang, SP, Wu, JW, Bourdages, H, Lefebvre, JF, Casavant, S, Leavitt, BR et al.. The catalytic function of hormone-sensitive lipase is essential for fertility in male mice. Endocrinology. 2014;155 (8):3047-53. doi: 10.1210/en.2014-1031. PubMed PMID:24797631 .
  • Kostro, D, Abdulkadir, A, Durr, A, Roos, R, Leavitt, BR, Johnson, H et al.. Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. Neuroimage. 2014;98 :405-15. doi: 10.1016/j.neuroimage.2014.04.057. PubMed PMID:24791746 .
  • Muller, M, Leavitt, BR. Iron dysregulation in Huntington's disease. J. Neurochem. 2014;130 (3):328-50. doi: 10.1111/jnc.12739. PubMed PMID:24717009 .
  • Ross, CA, Aylward, EH, Wild, EJ, Langbehn, DR, Long, JD, Warner, JH et al.. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10 (4):204-16. doi: 10.1038/nrneurol.2014.24. PubMed PMID:24614516 .
  • Park, KH, Franciosi, S, Leavitt, BR. Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nat Commun. 2013;4 :2906. doi: 10.1038/ncomms3906. PubMed PMID:24346342 PubMed Central PMC4965267.
  • Franciosi, S, Shim, Y, Lau, M, Hayden, MR, Leavitt, BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord. 2013;28 (14):1987-94. doi: 10.1002/mds.25663. PubMed PMID:24142393 .
  • Saft, C, Leavitt, BR, Epplen, JT. Clinical utility gene card for: Huntington's disease. Eur. J. Hum. Genet. 2014;22 (5):. doi: 10.1038/ejhg.2013.206. PubMed PMID:24105375 PubMed Central PMC3992568.
  • Ehrnhoefer, DE, Skotte, NH, Ladha, S, Nguyen, YT, Qiu, X, Deng, Y et al.. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet. 2014;23 (3):717-29. doi: 10.1093/hmg/ddt458. PubMed PMID:24070868 .
  • Mazarei, G, Budac, DP, Lu, G, Lee, H, Möller, T, Leavitt, BR et al.. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp. Neurol. 2013;249 :144-8. doi: 10.1016/j.expneurol.2013.08.007. PubMed PMID:23994717 .
  • Zhu, S, Tai, C, Petkau, TL, Zhang, S, Liao, C, Dong, Z et al.. Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Res. 2013;1530 :54-65. doi: 10.1016/j.brainres.2013.07.023. PubMed PMID:23887054 .
  • Mazarei, G, Budac, DP, Lu, G, Adomat, H, Tomlinson Guns, ES, Möller, T et al.. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J. Neurochem. 2013;127 (6):852-67. doi: 10.1111/jnc.12350. PubMed PMID:23786539 .
  • Petkau, TL, Zhu, S, Lu, G, Fernando, S, Cynader, M, Leavitt, BR et al.. Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice. Neurobiol. Aging. 2013;34 (11):2548-50. doi: 10.1016/j.neurobiolaging.2013.04.019. PubMed PMID:23702345 .
  • Tabrizi, SJ, Scahill, RI, Owen, G, Durr, A, Leavitt, BR, Roos, RA et al.. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12 (7):637-49. doi: 10.1016/S1474-4422(13)70088-7. PubMed PMID:23664844 .
  • Borowsky, B, Warner, J, Leavitt, BR, Tabrizi, SJ, Roos, RA, Durr, A et al.. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 2013;80 (21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. PubMed PMID:23616162 PubMed Central PMC3716347.
  • Read, J, Jones, R, Owen, G, Leavitt, BR, Coleman, A, Roos, RA et al.. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. J Huntingtons Dis. 2013;2 (2):159-75. doi: 10.3233/JHD-130051. PubMed PMID:25063513 .
  • Crawford, HE, Hobbs, NZ, Keogh, R, Langbehn, DR, Frost, C, Johnson, H et al.. Corpus callosal atrophy in premanifest and early Huntington's disease. J Huntingtons Dis. 2013;2 (4):517-26. doi: 10.3233/JHD-130077. PubMed PMID:25062736 .
  • Leavitt, BR, Thompson, LM. We are pleased to introduce this next volume of the Journal of Huntington's Disease. Introduction. J Huntingtons Dis. 2013;2 (1):1. doi: 10.3233/JHD-130003. PubMed PMID:25057106 .
  • Boxer, AL, Gold, M, Huey, E, Hu, WT, Rosen, H, Kramer, J et al.. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9 (2):189-98. doi: 10.1016/j.jalz.2012.03.003. PubMed PMID:23062850 PubMed Central PMC3562382.
  • Boxer, AL, Gold, M, Huey, E, Gao, FB, Burton, EA, Chow, T et al.. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9 (2):176-88. doi: 10.1016/j.jalz.2012.03.002. PubMed PMID:23043900 PubMed Central PMC3542408.
  • Stout, JC, Jones, R, Labuschagne, I, O'Regan, AM, Say, MJ, Dumas, EM et al.. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 2012;83 (7):687-94. doi: 10.1136/jnnp-2011-301940. PubMed PMID:22566599 PubMed Central PMC3368487.
  • Tang, B, Becanovic, K, Desplats, PA, Spencer, B, Hill, AM, Connolly, C et al.. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum. Mol. Genet. 2012;21 (14):3097-111. doi: 10.1093/hmg/dds132. PubMed PMID:22492998 PubMed Central PMC3384380.
  • Long, JD, Matson, WR, Juhl, AR, Leavitt, BR, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis. 2012;46 (3):625-34. doi: 10.1016/j.nbd.2012.02.012. PubMed PMID:22414782 PubMed Central PMC3784019.
  • Dumas, EM, Say, MJ, Jones, R, Labuschagne, I, O'Regan, AM, Hart, EP et al.. Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. J Huntingtons Dis. 2012;1 (1):97-106. doi: 10.3233/JHD-2012-120010. PubMed PMID:25063192 .
  • Leavitt, BR, Thompson, LM. Journal of Huntington's Disease. J Huntingtons Dis. 2012;1 (1):1. doi: 10.3233/JHD-2012-120001. PubMed PMID:25056612 .
  • Park, KH, Lu, G, Fan, J, Raymond, LA, Leavitt, BR. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons. J Huntingtons Dis. 2012;1 (1):89-96. doi: 10.3233/JHD-2012-129000. PubMed PMID:24353748 PubMed Central PMC3864911.
  • Scahill, RI, Hobbs, NZ, Say, MJ, Bechtel, N, Henley, SM, Hyare, H et al.. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp. 2013;34 (3):519-29. doi: 10.1002/hbm.21449. PubMed PMID:22102212 .
  • Petkau, TL, Neal, SJ, Milnerwood, A, Mew, A, Hill, AM, Orban, P et al.. Synaptic dysfunction in progranulin-deficient mice. Neurobiol. Dis. 2012;45 (2):711-22. doi: 10.1016/j.nbd.2011.10.016. PubMed PMID:22062772 .
  • Franciosi, S, Ryu, JK, Shim, Y, Hill, A, Connolly, C, Hayden, MR et al.. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012;45 (1):438-49. doi: 10.1016/j.nbd.2011.09.003. PubMed PMID:21946335 .
  • Sivananthan, SN, Leavitt, BR. Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. Neurobiol. Aging. 2011;32 (12):2326.e1-4. doi: 10.1016/j.neurobiolaging.2011.05.020. PubMed PMID:21741126 .
  • Fotovati, A, Abu-Ali, S, Wang, PS, Deleyrolle, LP, Lee, C, Triscott, J et al.. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011;71 (16):5569-78. doi: 10.1158/0008-5472.CAN-10-2805. PubMed PMID:21730024 .
  • Weir, DW, Sturrock, A, Leavitt, BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011;10 (6):573-90. doi: 10.1016/S1474-4422(11)70070-9. PubMed PMID:21601164 .
  • Hobbs, NZ, Pedrick, AV, Say, MJ, Frost, C, Dar Santos, R, Coleman, A et al.. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov. Disord. 2011;26 (9):1684-90. doi: 10.1002/mds.23747. PubMed PMID:21557312 .
  • Tabrizi, SJ, Scahill, RI, Durr, A, Roos, RA, Leavitt, BR, Jones, R et al.. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10 (1):31-42. doi: 10.1016/S1474-4422(10)70276-3. PubMed PMID:21130037 .
  • Bechtel, N, Scahill, RI, Rosas, HD, Acharya, T, van den Bogaard, SJ, Jauffret, C et al.. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010;75 (24):2150-60. doi: 10.1212/WNL.0b013e3182020123. PubMed PMID:21068430 PubMed Central PMC3013584.
  • Sturrock, A, Laule, C, Decolongon, J, Dar Santos, R, Coleman, AJ, Creighton, S et al.. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 2010;75 (19):1702-10. doi: 10.1212/WNL.0b013e3181fc27e4. PubMed PMID:21060093 PubMed Central PMC3033605.
  • Metzler, M, Gan, L, Mazarei, G, Graham, RK, Liu, L, Bissada, N et al.. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci. 2010;30 (43):14318-29. doi: 10.1523/JNEUROSCI.1589-10.2010. PubMed PMID:20980587 .
  • Sturrock, A, Leavitt, BR. The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol. 2010;23 (4):243-59. doi: 10.1177/0891988710383573. PubMed PMID:20923757 .
  • Petkau, TL, Neal, SJ, Orban, PC, MacDonald, JL, Hill, AM, Lu, G et al.. Progranulin expression in the developing and adult murine brain. J. Comp. Neurol. 2010;518 (19):3931-47. doi: 10.1002/cne.22430. PubMed PMID:20737593 .
  • Pouladi, MA, Xie, Y, Skotte, NH, Ehrnhoefer, DE, Graham, RK, Kim, JE et al.. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet. 2010;19 (8):1528-38. doi: 10.1093/hmg/ddq026. PubMed PMID:20097678 PubMed Central PMC2846162.
  • Becanovic, K, Pouladi, MA, Lim, RS, Kuhn, A, Pavlidis, P, Luthi-Carter, R et al.. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. 2010;19 (8):1438-52. doi: 10.1093/hmg/ddq018. PubMed PMID:20089533 PubMed Central PMC2846159.
  • Mazarei, G, Neal, SJ, Becanovic, K, Luthi-Carter, R, Simpson, EM, Leavitt, BR et al.. Expression analysis of novel striatal-enriched genes in Huntington disease. Hum. Mol. Genet. 2010;19 (4):609-22. doi: 10.1093/hmg/ddp527. PubMed PMID:19934114 PubMed Central PMC2807369.
  • Tabrizi, SJ, Langbehn, DR, Leavitt, BR, Roos, RA, Durr, A, Craufurd, D et al.. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8 (9):791-801. doi: 10.1016/S1474-4422(09)70170-X. PubMed PMID:19646924 PubMed Central PMC3725974.
  • Yeretssian, G, Doiron, K, Shao, W, Leavitt, BR, Hayden, MR, Nicholson, DW et al.. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc. Natl. Acad. Sci. U.S.A. 2009;106 (22):9016-20. doi: 10.1073/pnas.0813362106. PubMed PMID:19447924 PubMed Central PMC2690057.
  • Joshi, PR, Wu, NP, André, VM, Cummings, DM, Cepeda, C, Joyce, JA et al.. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009;29 (8):2414-27. doi: 10.1523/JNEUROSCI.5687-08.2009. PubMed PMID:19244517 PubMed Central PMC2670193.
  • Graham, RK, Pouladi, MA, Joshi, P, Lu, G, Deng, Y, Wu, NP et al.. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009;29 (7):2193-204. doi: 10.1523/JNEUROSCI.5473-08.2009. PubMed PMID:19228972 PubMed Central PMC2729178.
  • Hayden, MR, Leavitt, BR, Yasothan, U, Kirkpatrick, P. Tetrabenazine. Nat Rev Drug Discov. 2009;8 (1):17-8. doi: 10.1038/nrd2784. PubMed PMID:19116624 .
  • Fang, Q, Strand, A, Law, W, Faca, VM, Fitzgibbon, MP, Hamel, N et al.. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell Proteomics. 2009;8 (3):451-66. doi: 10.1074/mcp.M800231-MCP200. PubMed PMID:18984577 PubMed Central PMC2649809.
  • Orban, P, Devon, RS, Hayden, MR, Leavitt, BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handb Clin Neurol. 2007;82 :301-12. doi: 10.1016/S0072-9752(07)80018-2. PubMed PMID:18808900 .
  • Björkqvist, M, Wild, EJ, Thiele, J, Silvestroni, A, Andre, R, Lahiri, N et al.. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008;205 (8):1869-77. doi: 10.1084/jem.20080178. PubMed PMID:18625748 PubMed Central PMC2525598.
  • Semaka, A, Warby, S, Leavitt, BR, Hayden, MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov. Disord. 2008;23 (12):1794-5; author reply 1793. doi: 10.1002/mds.21820. PubMed PMID:18548612 .
  • Björkqvist, M, Leavitt, BR, Nielsen, JE, Landwehrmeyer, B, Ecker, D, Mulder, H et al.. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov. Disord. 2007;22 (13):1952-4. doi: 10.1002/mds.21447. PubMed PMID:17722045 .
  • Wong, D, Dwinnel, M, Schulzer, M, Nimmo, M, Leavitt, BR, Spacey, SD et al.. Ataxia and the role of antigliadin antibodies. Can J Neurol Sci. 2007;34 (2):193-6. . PubMed PMID:17598597 .
  • Dalrymple, A, Wild, EJ, Joubert, R, Sathasivam, K, Björkqvist, M, Petersén, A et al.. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007;6 (7):2833-40. doi: 10.1021/pr0700753. PubMed PMID:17552550 .
  • Kuhn, A, Goldstein, DR, Hodges, A, Strand, AD, Sengstag, T, Kooperberg, C et al.. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007;16 (15):1845-61. doi: 10.1093/hmg/ddm133. PubMed PMID:17519223 .
  • Butland, SL, Devon, RS, Huang, Y, Mead, CL, Meynert, AM, Neal, SJ et al.. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics. 2007;8 :126. doi: 10.1186/1471-2164-8-126. PubMed PMID:17519034 PubMed Central PMC1896166.
  • Van Raamsdonk, JM, Murphy, Z, Selva, DM, Hamidizadeh, R, Pearson, J, Petersén, A et al.. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007;26 (3):512-20. doi: 10.1016/j.nbd.2007.01.006. PubMed PMID:17433700 .
  • Van Raamsdonk, JM, Metzler, M, Slow, E, Pearson, J, Schwab, C, Carroll, J et al.. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 2007;26 (1):189-200. doi: 10.1016/j.nbd.2006.12.010. PubMed PMID:17276692 .
  • Van Raamsdonk, JM, Pearson, J, Murphy, Z, Hayden, MR, Leavitt, BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci. 2006;7 :80. doi: 10.1186/1471-2202-7-80. PubMed PMID:17147801 PubMed Central PMC1762017.
  • Zhang, Y, Leavitt, BR, van Raamsdonk, JM, Dragatsis, I, Goldowitz, D, MacDonald, ME et al.. Huntingtin inhibits caspase-3 activation. EMBO J. 2006;25 (24):5896-906. doi: 10.1038/sj.emboj.7601445. PubMed PMID:17124493 PubMed Central PMC1698892.
  • Leavitt, BR, Hayden, MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?. Nat Clin Pract Neurol. 2006;2 (10):536-7. doi: 10.1038/ncpneuro0299. PubMed PMID:16990826 .
  • Mackenzie, IR, Butland, SL, Devon, RS, Dwosh, E, Feldman, H, Lindholm, C et al.. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurol. 2006;6 :32. doi: 10.1186/1471-2377-6-32. PubMed PMID:16945149 PubMed Central PMC1570137.
  • Björkqvist, M, Petersén, A, Nielsen, J, Ecker, D, Mulder, H, Hayden, MR et al.. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin. Genet. 2006;70 (1):78-9. doi: 10.1111/j.1399-0004.2006.00636.x. PubMed PMID:16813610 .
  • Graham, RK, Deng, Y, Slow, EJ, Haigh, B, Bissada, N, Lu, G et al.. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125 (6):1179-91. doi: 10.1016/j.cell.2006.04.026. PubMed PMID:16777606 .
  • Devon, RS, Orban, PC, Gerrow, K, Barbieri, MA, Schwab, C, Cao, LP et al.. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 2006;103 (25):9595-600. doi: 10.1073/pnas.0510197103. PubMed PMID:16769894 PubMed Central PMC1480452.
  • Guidetti, P, Bates, GP, Graham, RK, Hayden, MR, Leavitt, BR, MacDonald, ME et al.. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 2006;23 (1):190-7. doi: 10.1016/j.nbd.2006.02.011. PubMed PMID:16697652 .
  • Van Raamsdonk, JM, Gibson, WT, Pearson, J, Murphy, Z, Lu, G, Leavitt, BR et al.. Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet. 2006;15 (9):1513-23. doi: 10.1093/hmg/ddl072. PubMed PMID:16571604 .
  • Leavitt, BR, van Raamsdonk, JM, Shehadeh, J, Fernandes, H, Murphy, Z, Graham, RK et al.. Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 2006;96 (4):1121-9. doi: 10.1111/j.1471-4159.2005.03605.x. PubMed PMID:16417581 .
  • Van Raamsdonk, JM, Murphy, Z, Slow, EJ, Leavitt, BR, Hayden, MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005;14 (24):3823-35. doi: 10.1093/hmg/ddi407. PubMed PMID:16278236 .
  • Graham, RK, Slow, EJ, Deng, Y, Bissada, N, Lu, G, Pearson, J et al.. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 2006;21 (2):444-55. doi: 10.1016/j.nbd.2005.08.007. PubMed PMID:16230019 .
Search PubMed